1. Home
  2. SPCE vs IKT Comparison

SPCE vs IKT Comparison

Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

HOLD

Current Price

$3.05

Market Cap

331.6M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.31

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCE
IKT
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.6M
220.5M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SPCE
IKT
Price
$3.05
$2.31
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$3.06
$5.00
AVG Volume (30 Days)
4.8M
360.8K
Earning Date
05-14-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
60.84
57.76
EPS
N/A
N/A
Revenue
$1,544,000.00
N/A
Revenue This Year
$2,270.73
N/A
Revenue Next Year
$880.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.13
$1.33
52 Week High
$8.90
$2.61

Technical Indicators

Market Signals
Indicator
SPCE
IKT
Relative Strength Index (RSI) 52.71 46.52
Support Level $2.84 $2.29
Resistance Level $3.29 $2.56
Average True Range (ATR) 0.15 0.10
MACD 0.01 -0.02
Stochastic Oscillator 56.00 20.28

Price Performance

Historical Comparison
SPCE
IKT

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: